Envoy Medical Statistics
Total Valuation
Envoy Medical has a market cap or net worth of $55.68 million. The enterprise value is $53.07 million.
Important Dates
The next estimated earnings date is Monday, March 30, 2026, before market open.
| Earnings Date | Mar 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Envoy Medical has 76.88 million shares outstanding. The number of shares has increased by 12.58% in one year.
| Current Share Class | 76.88M |
| Shares Outstanding | 76.88M |
| Shares Change (YoY) | +12.58% |
| Shares Change (QoQ) | +2.19% |
| Owned by Insiders (%) | 37.17% |
| Owned by Institutions (%) | 2.71% |
| Float | 45.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 267.72 |
| Forward PS | 266.31 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 255.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.64
| Current Ratio | 0.64 |
| Quick Ratio | 0.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.35 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -145.31% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 2,532.09% |
| Weighted Average Cost of Capital (WACC) | 18.22% |
| Revenue Per Employee | $4,952 |
| Profits Per Employee | -$681,214 |
| Employee Count | 42 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.50 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.13% in the last 52 weeks. The beta is 2.09, so Envoy Medical's price volatility has been higher than the market average.
| Beta (5Y) | 2.09 |
| 52-Week Price Change | -47.13% |
| 50-Day Moving Average | 0.67 |
| 200-Day Moving Average | 1.07 |
| Relative Strength Index (RSI) | 54.16 |
| Average Volume (20 Days) | 1,699,517 |
Short Selling Information
The latest short interest is 430,606, so 0.56% of the outstanding shares have been sold short.
| Short Interest | 430,606 |
| Short Previous Month | 475,443 |
| Short % of Shares Out | 0.56% |
| Short % of Float | 0.94% |
| Short Ratio (days to cover) | 3.48 |
Income Statement
In the last 12 months, Envoy Medical had revenue of $208,000 and -$28.61 million in losses. Loss per share was -$1.36.
| Revenue | 208,000 |
| Gross Profit | -612,000 |
| Operating Income | -20.43M |
| Pretax Income | -21.79M |
| Net Income | -28.61M |
| EBITDA | -20.16M |
| EBIT | -20.43M |
| Loss Per Share | -$1.36 |
Full Income StatementBalance Sheet
The company has $3.56 million in cash and $946,000 in debt, with a net cash position of $2.61 million or $0.03 per share.
| Cash & Cash Equivalents | 3.56M |
| Total Debt | 946,000 |
| Net Cash | 2.61M |
| Net Cash Per Share | $0.03 |
| Equity (Book Value) | -7.53M |
| Book Value Per Share | -0.32 |
| Working Capital | -3.23M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.61 million and capital expenditures $527,000, giving a free cash flow of -$17.08 million.
| Operating Cash Flow | -17.61M |
| Capital Expenditures | 527,000 |
| Free Cash Flow | -17.08M |
| FCF Per Share | -$0.22 |
Full Cash Flow StatementMargins
| Gross Margin | -294.23% |
| Operating Margin | -9,824.04% |
| Pretax Margin | -10,475.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Envoy Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.58% |
| Shareholder Yield | n/a |
| Earnings Yield | -51.38% |
| FCF Yield | -30.67% |
Analyst Forecast
The average price target for Envoy Medical is $9.50, which is 1,211.61% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.50 |
| Price Target Difference | 1,211.61% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Envoy Medical has an Altman Z-Score of -59.7 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -59.7 |
| Piotroski F-Score | 2 |
